

ARGENX SE

ISIN: NL0010832176 WKN: - Asset Class: **Stock**

Company

2024/06/28 17:35:03



Price

408.60

EUR

Difference

-1.87%(-7.80)



Contact Details

ARGENX SE Tel: +31-76-303-04-88
-- Fax: +
Laarderhoogtweg 25 Web: <http://www.argen-x.com>
1101 EB Amsterdam E-mail: info@argenx.com

Company Profile

argenx SE is a global immunology company, which engages in improving the lives of people suffering from severe autoimmune diseases. It operates through the following geographical segments: United States, Japan, EMEA, and China. The company was founded by Hans J. W. de Haard, Torsten Dreier, and Tim van Hauwermeiren in 2008 and is headquartered in Amsterdam, the Netherlands.

Financial figures, Fiscal year: from 01.01. to 31.12.

Financial figures	2023		2022		2021	
	Assets	Liabilities and equity	Assets	Liabilities and equity	Assets	Liabilities and equity
Current assets	3,733,071,000		2,599,389,000		2,236,168,000	
Common stock capital		6,389,000		6,221,000		5,481,000
Fixed assets	379,053,000		337,374,000		270,227,000	
Equity capital of a company		3,709,326,000		2,636,401,000		2,228,476,000
Cash and cash equivalents	1,854,744,000		793,536,000		1,237,889,000	
Accrued liabilities		1,311,000		815,000		366,000
Other assets	-		-		-	
Current liabilities		382,920,000		283,229,000		264,895,000
Prepayments and accrued income	-		-		-	
Non-current liabilities		19,877,000		17,132,000		13,024,000
Different income		-		-		-
Other liabilities		0		0		0
Total assets	4,112,124,000	4,112,124,000	2,936,763,000	2,936,763,000	2,506,396,000	2,506,396,000

Balance notes

	2023	2022	2021
Accounting standard	IFRS	IFRS	IFRS
Employees	1,148	843	650
Equity ratio	90.20%	89.77%	88.91%
Debt-equity ratio	10.86%	11.39%	12.47%

Others

	2023	2022	2021
Tax Expense Rate	11.36%	5.24%	1.32%

ARGENX SE

ISIN: NL0010832176 WKN: - Asset Class: **Stock**

Income statement

	2023	2022	2021
Turnover	1,134,306,000	390,824,000	420,714,000
Net income	-272,915,000	-675,177,000	-345,407,000
EBIT	-388,448,746	-733,307,168	-352,042,061
Operating income before taxes	-303,297,000	-711,852,000	-350,016,000
Cash Flow	-302,996,000	-808,450,000	-511,183,000
Net interest income	85,150,000	21,454,000	2,025,000
Research and development expenses	697,377,000	534,013,000	487,975,000
Income taxes	-34,462,000	-37,319,000	-4,609,000
Result from investments in subsidiaries, associates and other	-4,080,000	-644,000	0
Revenues per employee	988,071	463,611	647,254

Board of Directors

Peter K. M. Verhaeghe	Chairman of Supervisory Board
Ana Cespedes	Member of Supervisory Board
Brian Kotzin	Member of Supervisory Board
Joseph deBethizy	Member of Supervisory Board
Pamela Klein	Member of Supervisory Board
Anthony Adam Rosenberg	Member of Supervisory Board
Camilla Sylvest	Member of Supervisory Board
James Daly	Member of Supervisory Board
Steve Kroghes	Member of Supervisory Board

Members of Management Board

Tim Van Hauwermeiren	Chairman of Managing Board
Andria Wilk	Member of Executive Committee
Arjen Lemmen	Member of Executive Committee
Beth DelGiaccio	Member of Executive Committee
Filip Borgions	Member of Executive Committee
Karen Massey	Member of Executive Committee
Karl Gubitz	Member of Executive Committee
Luc Truyen	Member of Executive Committee
Malini Moorthy	Member of Executive Committee
Marc Schorpion	Member of Executive Committee
Peter Ulrichs	Member of Executive Committee